17326-09-9

Basic information

• Product Name: 4H-Pyrido[1,2-a]pyriMidin-4-one,2-hydroxy-9-Methyl-
• Synonyms: 4H-Pyrido[1,2-a]pyriMidin-4-one,2-hydroxy-9-Methyl-
• CAS NO: 17326-09-9
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.18
• Mol File: 17326-09-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 323.7°Cat760mmHg
• Flash Point: 149.6°C
• Appearance: /
• Density: 1.35g/cm³
• Vapor Pressure: 2.03E-05mmHg at 25°C
• Refractive Index: 1.653
• PKA: 4.50±1.00(Predicted)
• CAS DataBase Reference: 4H-Pyrido[1,2-a]pyriMidin-4-one,2-hydroxy-9-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrido[1,2-a]pyriMidin-4-one,2-hydroxy-9-Methyl-(17326-09-9)
• EPA Substance Registry System: 4H-Pyrido[1,2-a]pyriMidin-4-one,2-hydroxy-9-Methyl-(17326-09-9)

Safety Data

• Hazardous Substances Data: 17326-09-9(Hazardous Substances Data)

Usage

General Description

The chemical 4H-Pyrido[1,2-a]pyrimidin-4-one,2-hydroxy-9-methyl- is a heterocyclic compound with a pyrido and pyrimidine ring system. It is also known as febuxostat, a medication used to treat gout and hyperuricemia. The presence of a hydroxy and methyl group on the structure of the compound indicates its pharmacological activity, as these functional groups are commonly found in drugs. Febuxostat works by inhibiting the enzyme xanthine oxidase, which is involved in the production of uric acid in the body. By reducing the levels of uric acid, febuxostat helps to alleviate the symptoms of gout and prevent the formation of urate crystals in the joints and kidneys.

InChI:InChI=1/C9H8N2O2/c1-6-3-2-4-11-8(13)5-7(12)10-9(6)11/h2-5,13H,1H3

Upstream product

• 1603-40-3 3-methylpyridin-2-ylamine 
• 15781-70-1 malonic acid bis-(2,4,6-trichloro-phenyl) ester 
• 105-53-3 diethyl malonate 

Downstream Products

• 17326-27-1 2-chloro-9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carbaldehyde 
• 17326-22-6 2-Chlor-9-methyl-4-oxo-4H-pyrido<1,2-a>pyrimidin 

Relevant articles and documents

Structure-activity relationship of spop inhibitors against kidney cancer

Speckle-type POZ protein (SPOP) is overexpressed in the nucleus and misallocated in the cytoplasm in almost all the clear-cell renal cell carcinomas (ccRCCs), which leads to kidney tumorigenesis. Previously, we elucidated that the oncogenic SPOP-signaling pathway in ccRCC could be suppressed by 6b that inhibits SPOP-mediated protein interactions. Herein, we have established a structure-activity relationship for 6b analogues as SPOP inhibitors. Compound 6lc suppresses the viability and inhibits the colony formation of ccRCC cell lines driven by cytoplasmic SPOP, superior to 6b. Compound 6lc binds to the SPOP protein in vitro and disrupts SPOP binding to phosphatase-and-tensin homologue (PTEN) in HEK293T cells, which causes the observable phenomena: a decline in the ubiquitination of PTEN, elevated levels of both PTEN and dual-specificity phosphatase 7, and decreased levels of phosphorylated AKT and ERK when ccRCC cell lines are exposed to 6lc in a dose-response manner. Taken together, compound 6lc is a potent candidate against kidney tumorigenesis.

Characterization and structure-activity relationship study of iminodipyridinopyrimidines as novel hepatitis C virus inhibitor

Upon high-throughput screening of synthetic small molecule libraries with the infectious hepatitis C virus (HCV) cell culture system, we identified an iminodipyridinopyrimidine (IDPP) scaffold. IDPP did not inhibit HCV replication, but exhibited very potent inhibitory activity on early and late steps of HCV life cycle. Applying an intensive structure-activity relationship (SAR) study, a promising IDPP Lead compound (12c) with excellent potency (EC50 = 10 nM), high safety margin (SI > 2000), and an acceptable stability in human and rat liver microsomes (t1/2 >60 min) was identified. Overall, our results suggest that the IDPP scaffold could be used for the development of novel HCV interventions.

PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES

The present invention relates to compounds of Formula I as described herein or a 1 pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.